GlassScriptPhysician profile
Eric C Storts
NPI 1881980605
$100,597.12
in general payments reported to CMS, 2019-2025
21 companies · $4,792 in 2025
The $4,792 reported for 2025 was more than what 96% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $11K · 2021: $32K · 2022: $10K · 2023: $18K · 2024: $8,762 · 2025: $4,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $21K · Consulting Fee: $7,625 · Travel and Lodging: $1,934 · Food and Beverage: $946 · Education: $61.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $21,120.62 |
| Consulting Fee | $7,625.00 |
| Travel and Lodging | $1,934.35 |
| Food and Beverage | $946.16 |
| Education | $61.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vilex LLC | $37,022.18 | 2021-2025 | Alphalok |
| Extremity Medical | $32,327.15 | 2020-2024 | Omni Stable Af, Io Fix |
| Dne LLC | $23,500.00 | 2019-2021 | |
| In2bones USA, LLC | $6,243.97 | 2019-2021 | |
| Smith+Nephew, INC. | $503.46 | 2019-2025 | Grafix Pl, Oasis, Panta 2 |
| Stryker Corporation | $175.79 | 2019-2024 | Prophecy |
| Kerecis Limited | $167.96 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $166.08 | 2019-2024 | |
| Osiris Therapeutics INC. | $95.85 | 2019 | |
| Paratek Pharmaceuticals, INC. | $76.24 | 2024-2025 | Nuzyra |
| Paladin Technology Solutions | $63.52 | 2023 | |
| Fusion Orthopedics USA, LLC | $42.66 | 2025 | |
| Polarityte, INC. | $42.46 | 2020 | |
| Conmed Corporation | $37.32 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $27.36 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $25.60 | 2025 | Durolane |
| Misonix INC | $23.54 | 2020 | |
| Kci USA, INC. | $20.56 | 2019 | |
| Solventum Corporation | $15.35 | 2025 | Activ.A.C. |
| 3m Company | $11.18 | 2019 | |
| Amniox Medical, INC. | $8.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Storts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.